Upcoming IPOs


Small Caps’ upcoming IPOs page offers investors a preview of companies that are currently planning to list on the ASX (Australian Stock Exchange) and access to live deals. We include details of the IPO (Initial Public Offering) including company name, ASX code, issue price, capital sought and more. Investors can also view and track the performance of companies that have recently listed.

Total number of IPOs in 2019 = 30

Company nameASX codeIssue priceRaiseFocusInformation
AppsVillage AustraliaAPV$0.20$6mApp developerWebsite
Imricor Medical SystemsIMR$0.83$13mMRI-compatible productsWebsite
Magellan High Conviction TrustMHH$1.50$250mListed investment trustWebsite
Nemex ResourcesNXR$0.20$5mMineral explorationWebsite
Nicheliving HoldingsNLH$0.50$12mResidential developerWebsite
OptiCommOPC$2.00$42.3mTelecommunicationsWebsite
OsteoporeOSX$0.20$5.2m3D printed bioresorbable implantsWebsite
Partners Group Global Income FundPGG$2.00$550mListed investment trustWebsite
SupastructureSUP$0.50$70mCivil engineering and infrastructureWebsite
Tartana ResourcesTNA$0.20$6mMining explorationWebsite
Trigg MiningTMG$0.20$4.5mSulphate of potashWebsite

2019 IPO tracker


Track the performance of companies that have listed on the ASX in 2019.

2018 IPO tracker


Track the performance of companies that listed on the ASX in 2018.

2017 IPO tracker


Track the performance of companies that listed on the ASX in 2017.

IPO articles


Cannvalate IPO Dr Amit Vohra medicinal cannabis Sonic Healthcare ASX SHL

Cannvalate strengthens board by recruiting Sonic Healthcare senior executive ahead of IPO

Medicinal cannabis company Cannvalate is getting its ducks in a row ahead of its planned IPO, strengthening its board with the appointment of Dr Amit Vohra as chief operating officer. Dr Vohra was formerly the...
Sezzle ASX SZL buy now pay later stock IPO

Buy now, pay later start-up Sezzle makes sizzling ASX debut

US payments start-up Sezzle (ASX: SZL) has made an impressive debut on the Australian Stock Exchange this morning, following the completion of an oversubscribed $43.6 million initial public offering. The company’s share price rose 82%...
Invex Therapeutics ASX IXC repurpose diabetic drug brain disorders Exenatide IPO

Invex Therapeutics aims to repurpose a diabetic drug for brain disorders

Biopharmaceutical company Invex Therapeutics is planning to make its ASX debut this week under the ticker code “IXC” with ambitions to repurpose an approved diabetes drug for some neurological conditions. Through its initial public offering...

Investor tools